GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side (Q36720912)

15 August 2017

1 reference

title

GARDASIL: prophylactic human papillomavirus vaccine development--from bench top to bed-side (English)

1 reference

15 August 2017

0 references

1 reference

human papillomavirus vaccine

29 September 2024

author name string

Shi L

1

1 reference

15 August 2017

Sings HL

2

1 reference

15 August 2017

Bryan JT

3

1 reference

15 August 2017

Wang B

4

1 reference

15 August 2017

Wang Y

5

1 reference

15 August 2017

Mach H

6

1 reference

15 August 2017

Kosinski M

7

1 reference

15 August 2017

Washabaugh MW

8

1 reference

15 August 2017

Sitrin R

9

1 reference

15 August 2017

Barr E

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

Clinical Pharmacology & Therapeutics

15 August 2017

published in

1 reference

15 August 2017

volume

81

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

259-264

1 reference

Evaluation of the thermal stability of Gardasil.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

The global health burden of infection-associated cancers in the year 2002

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Efficacy and other milestones for human papillomavirus vaccine introduction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Stabilization of human papillomavirus virus-like particles by non-ionic surfactants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100055

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100055

1 reference

Dimensions Publication ID

15 August 2017

1016642853

0 references

1 reference